


Form PTO-1449 (Rev. 8-88)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. C-3523/2/US	Serial No. 09/933,366
O I P INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Sandra M. Sims	Filing Date August 20, 2001
		Group No. 1614 4623	

FEB 03 2003
TECH CENTER 1600/2900



FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
CJM	WO00/18387	Apr 06, 2000	WIPO	A61K	31/00		
CJM	WO01/19366	Mar 22, 2001	WIPO	A61K	31/422		
CJM	WO02/30395	Apr 18, 2002	WIPO	A61K	9/00		

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

	Hilliard, (1999), The Complexation of Hydroxypropyl-β-Cyclodextrin with Oxazolidinones: A Study on the Effect of Cyclodextrins in Terms of Solubility Enhancement, Increased Dissolution Rate, and Precipitation Inhibition.
--	--

Examiner	Date Considered
	7/30/03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

RECEIVED

Form PTO-1449 (Rev. 8-88)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. C-3523/2/US
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Sims
		Filing Date August 20, 2001
		Group No. 1623-1614



U.S. PATENT DOCUMENTS

Examiner	Patent					Filing Date
Initial	Number	Issue Date	Name	Class	Subclass	If Appropriate
CM	AB 4,524,068	Jun 18, 1985	Szejtli <i>et al.</i>	514	58	
	AC 4,599,327	Jul 08, 1986	Nógrádi <i>et al.</i>	514	58	
	AD 4,727,064	Feb 23, 1988	Pitha	514	58	
	AE 5,024,998	Jun 18, 1991	Boder	514	58	
	AF 5,134,127	Jul 28, 1992	Stella <i>et al.</i>	514	58	
	AG 5,164,510	Nov 17, 1992	Brickner	548	231	
	AH 5,231,188	Jul 27, 1993	Brickner	548	221	
	AI 5,324,718	Jun 28, 1994	Loftsson	514	58	
	AJ 5,376,645	Dec 27, 1994	Stella <i>et al.</i>	514	58	
	AK 5,486,508	Jan 23, 1996	Nishida <i>et al.</i>	514	58	
	AL 5,565,571	Oct 15, 1996	Barbachyn <i>et al.</i>	546	144	
	AM 5,627,181	May 06, 1997	Riedl <i>et al.</i>	514	236.8	
	AN 5,652,238	Jul 29, 1997	Barbachyn <i>et al.</i>	514	235.8	
	AO 5,670,530	Sep 23, 1997	Chen <i>et al.</i>	514	366	
	AP 5,688,792	Nov 18, 1997	Barbachyn <i>et al.</i>	514	235.5	
	AQ 5,698,574	Dec 16, 1997	Riedl <i>et al.</i>	514	376	
	AR 5,756,546	May 26, 1998	Pirotte <i>et al.</i>	514	605	
	AS 5,807,895	Sep 15, 1998	Stratton <i>et al.</i>	514	573	
	AT 5,824,668	Oct 20, 1998	Rubinfeld <i>et al.</i>	514	170	
	AU 5,837,870	Nov 17, 1998	Pearlman <i>et al.</i>	544	137	
	AV 5,874,418	Feb 23, 1999	Stella <i>et al.</i>	514	58	
	AW 5,910,504	Jun 08, 1999	Hutchinson	514	376	Aug 04, 1997
	AX 6,046,177	Apr 04, 2000	Stella <i>et al.</i>	514	58	Jan 13, 1999
	AY 6,069,145	May 30, 2000	Betts	514	252	Jul 27, 1998
	AZ 6,133,248	Oct 17, 2000	Stella	514	58	Jun 12, 1998
	BA 6,284,747	Sep 04, 2001	Rubinfeld	514	58	Oct 05, 2000
	BB 6,319,020	Nov 13, 2001	Whittle <i>et al.</i>	424	439	Jul 31, 2000
	BC 6,407,079	Jun 18, 2002	Müller <i>et al.</i>	514	58	

Examiner	Date Considered
CM	7-30-03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 12

RECEIVED
TECH CENTER 1600/2900
SEP 05 2002
D9933,366

Frm PTO-1449 (Rev. 8-88)	U.S. Department of Commerce Patent and Trad mark Offic		Attorney Docket No. C-3523/2/US	Serial No. 1623-1614
O INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)			Applicant Sims	
			Filing Date August 20, 2001	Group No.

*SEP 03 2002
PATENT & TRADEMARK OFFICE*

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation Yes No
CM	BD EP 0 340 171	Nov 02, 1989	WIPO	C08B	37/16	
	BE WO 85/02767	Jul 04, 1985	WIPO	A61K	9/18	
	BF WO 96/32135	Oct 17, 1996	WIPO	A61K	47/48	
	BG WO 96/38175	Dec 05, 1996	WIPO	A61K	47/48	
	BH WO 97/36935	Oct 09, 1997	WIPO	C08B	37/16	
	BI WO 97/39770	Oct 30, 1997	WIPO	A61K	38/55	
	BJ WO 98/37884	Sep 03, 1998	WIPO	A61K	31/40	
	BK WO 98/55148	Dec 10, 1998	WIPO	A61K	47/48	
	BL WO 98/58677	Dec 30, 1998	WIPO	A61K	47/40	
	BM WO 99/24073	May 20, 1999	WIPO	A61K	47/48	
	BN WO 99/24393	May 20, 1999	WIPO	C07D	233/16	
	BO WO 99/27932	Jun 10, 1999	WIPO	A61K	31/495	

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

CM	BP	Bekers <i>et al.</i> Drug Development and Industrial Pharmacy. 17, 1503-1549. (1991).
	BQ	Loftsson. Pharmazie. 53, 733-740. (1998).
	BR	Rajewski. Pharmaceutical Applications of Cyclodextrins. In Journal of Pharmaceutical Sciences. 85(11), pp. 1154-1159. (1996).
	BS	Szejtli Cyclodextrins and Their Inclusion Complexes. Choin Research Center, Hungary. pp. 204-232. (1982)
	BT	Szejtli. Medical Research Reviews. 14, 353-386. (1994).
	BU	Zhang <i>et al.</i> Expert Opinion on Therapeutic Patents. 9, 1697-1717. (1999).

Examiner	Date Considered
CM	7/30/03


*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAY 22 2003

TECH CENTER 1600/2000

Sheet 1 of 2

Form PTO-1449
(Rev. 3-03)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number

3523/2/US

Application Number

09/933,366

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

First Named Inventor

Sandra M. Sims

Filing Date

August 20, 2001

Group Art Unit

1623

1614

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date If Appropriate
CM	US 5,538,721	Jul 23, 1996	Babcock et al.	424	78.04	
CM	US 6,337,329	Jan 08, 2002	Cochran et al.	514	235.8	
CM	US 2002/0156072	Oct 24, 2002	Barbachyn et al.	514	227.8	

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

CM	Arima et al., (2001), Comparative Studies of the Enhancing Effects of Cyclodextrins on the Solubility and Oral Bioavailability of Tacrolimus in Rats, <i>Journal of Pharmaceutical Sciences</i> , Vol. 90, No. 6, pp. 690-701.
	Conners, (1997), The Stability of Cyclodextrin Complexes in Solution, <i>Chem. Rev.</i> 97, pp. 1325-1357.
	Fauci et al., (2002), Computer-aided molecular modeling techniques for predicting the stability of drug-cyclodextrin inclusion complexes in aqueous solutions, 358, pp. 383-390.
	Lipkowitz, (1998), Applications of Computational Chemistry to the Study of Cyclodextrins, <i>Chem. Rev.</i> 98, ppo. 1829-1873.
	Lotsson et al., (1989), Effects of 2-hydroxypropyl- β -cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17 β -estradiol, <i>Acta Pharm. Nord.</i> , 1(4), pp. 185-194.
	Loftsson, et al., (1991), Solubilization and stabilization of drugs through cyclodextrin complexation, <i>Acta Pharm. Nord.</i> , 3(4), pp. 215-217.
	Loftsson et al., (1996), Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization, <i>Journal of Pharmaceutical Sciences</i> , Vol. 85, No. 10, pp. 1017-1025.
	Pagington, (1987), β -Cyclodextrin: the success of molecular inclusion, <i>Chemistry in Britain</i> , pp. 455-458.
	Pitha et al., (1983), Molecular Encapsulation of Drugs By Cyclodextrins And Congeners, <i>Controlled Drug Delivery</i> , Vol. 1, pp. 125-148.
	Pitha et al., (1986), Hydroxypropyl- β -cyclodextrin: preparation and characterization; effects on solubility of drugs, <i>International Journal of Pharmaceutics</i> , 29, pp. 73-82.
	Schneider et al., (1998), NMR Studies of Cyclodextrins and Cyclodextrin Complexes, <i>Chem. Rev.</i> , 98, pp. 1755-1785.
	Stella, (1997), Cyclodextrins: Their Future in Drug Formulation and Delivery, <i>Pharmaceutical Research</i> , Vol. 14, No. 5., pp. 556-567.
	Szejtli, (1998), Introduction and General Overview of Cyclodextrin Chemistry, <i>Chem. Rev.</i> , 98, pp. 1743-1753.
CM	Uekama, (1987), Cyclodextrin Inclusion Compounds: Effects on Stability and Bio-Pharmaceutical Properties, <i>Topics in Pharmaceutical Sciences</i> , pp. 181-194.

Examiner

Date Considered

CM

7-30-03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 22 2003

TECH CENTER 1600/2000

Sheet 2 of 2

Form PTO-1449
(R. v. 3-03)U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number

Application Number

3523/2/US

09/933,366

First Named Inventor

Sandra M. Sims

Filing Date

August 20, 2001

Group Art Unit

1623 1614

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

*CM*Uekama et al., (1987), Cyclodextrins in Drug Carrier Systems, *Critical Reviews in Therapeutic Drug Carrier Systems*, 3(1), pp. 1-40.*CM*Uekama et al., (1998), Cyclodextrin Drug Carrier System, *Chem. Rev.*, 98, pp. 2045-2076.

Examiner

CM

Date Considered

7-30-03

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

